13 results about "Auto antigen" patented technology

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The application relates to the technical field of biological medicine, and discloses a drug composition containing nuclear autoantigen sperm protein for promoting myocardial regeneration and repair and application, which comprises an NASP gene; the nucleotide sequence of the NASP gene is shown as SEQ ID NO:1, and the amino acid sequence encoded by the NASP gene is shown as SEQ ID NO:2. The drug composition can promote the number of myocardial cells, repair the necrotic myocardium, and thus improve acute myocardial infarction at the gene level.

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to two or more auto-antigen(s). The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

A platform for therapy provides: a chimeric molecule comprising one or more auto-antigens linked by a linker to a fluorescent protein; a chimeric molecule comprising three or more components linked by linker, the components comprising two or more auto-antigens of an autoimmune disease and one or more ablative molecule and / or toxin or one or more fluorescent molecules; a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to an autoimmune disease associated HLA class or HLA class II molecule and one or more ablative molecules and / or toxins or one or more fluorescent molecules; and a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to a disease associated T-cell receptor and one or more fluorescent molecules or one or more ablative molecule and / or toxin

The invention provides an MHC class I autoantigen peptide for inducing immune tolerance. The amino acid sequence of the MHC class I autoantigen peptide is shown as SEQ ID NO. 4. The invention also provides a DNA (Deoxyribose Nucleic Acid) molecule for coding the MHC class I autoantigen peptide for inducing immune tolerance. The invention also provides a recombinant vector which contains the DNA molecule. The invention also provides application of the polypeptide in preparation of drugs for preventing or treating autoimmune diseases. The autoantigen peptide provided by the invention is derived from an autoantigen peptide presented on the surface of an activated CD4 + T cell, and can be specifically recognized by a self-reactive CD8 + T cell, so that immune response is induced, and regulation and control on a pathogenic T cell are realized. Through the mechanism, the antigen peptide can be used for inducing immune tolerance of the body, and has application value in improving or treating autoimmune diseases.

The present invention relates to an autoantigen-specific nanofusion vaccine composition for the treatment of systemic sclerosis, the composition being for simultaneous immunomodulation and antifibrosis. A nanofusion body carrying a vimentin peptide according to the present invention was found to inhibit tissue fibrosis in systemic sclerosis, reduce the amount of autoantibodies in serum, and regulate the expression of immune-regulatory cells and pathogenic cells associated with systemic sclerosis. The nanofusion body was also found to inhibit tissue fibrosis and to exhibit enhanced anti-fibrotic effects, when co-administered with a vimentin antibody, in an animal model reflecting the immune status of systemic sclerosis patients. In addition, the nano-vaccine was found to decrease the expression of fibrotic and pathogenic factors in tissues and was also found to improve disease activity not only in vimentin-specific systemic sclerosis but also in infection-associated systemic sclerosis.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The invention discloses an establishment method and application of a type-1 autoimmune hepatitis mouse model, and relates to the technical field of biology, and the technical key points are as follows: an adenovirus is combined with an overexpression Sepsecs plasmid to realize continuous expression of autoantigen in the liver, a chronic liver inflammation model conforming to type-1 AIH characteristics is successfully induced in a mouse body for the first time, and the mouse model has a good application prospect. The model shows clinical pathological characteristics of continuous infiltration of inflammatory cells, abnormal liver function, autoantibody generation, hepatic tissue fibrosis and the like, and has good stability and repeatability. At present, no type 1 AIH mouse model constructed by using the Sepsecs antigen is publically reported at home and abroad, and the technical blank in the field of type 1 AIH chronic animal models is filled. The model can be used for AIH pathogenesis research, autoantigen screening, novel diagnostic marker discovery, immune intervention means evaluation and clinical verification before new medicine, has wide scientific research and industrial application prospects, and provides an ideal experimental animal model platform.

The invention relates to a diagnostic kit and methods for detecting and quantifying autoantibodies associated with the onset of type 1 diabetes (T1D). The kit comprises recombinant antigen molecules fused to bioluminescent reporter proteins for the detection of autoantibodies directed against self-antigens expressed by pancreatic islet beta cells. The presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The invention provides an antibody which can competitively inhibit an autoantibody, effectively prevent or treat immune diseases related to decline of the function of an autoantigen, and has no side effect. Meanwhile, the invention also provides a pharmaceutical composition which contains the antibody and is used for treating immune diseases.

Disclosed herein are high performance biomarkers and panel for small cell lung cancer (SCLC) early detection useful for identifying, diagnosing and treating SCLC patients at an early stage. The method of detecting and diagnosing small cell lung cancer (SCLC) includes contacting a sample from a subject suspected of being at-risk of acquiring or having SCLC with at least two SCLC-specific autoantibody molecules and detecting binding of four different protein types—SCLC autoantibody-antigen complexes, SCLC uncomplexed autoantibodies, SCLC associated proteins and SCLC glycoproteins—in the sample, thereby detecting SCLC in the subject.

The invention provides an ionizable lipid, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of drug delivery. The invention provides an ionizable lipid, which can realize specific expression of a nucleic acid drug in the spleen without introducing a targeting ligand for modification, and effectively avoids off-target expression of non-target organs such as liver and the like. The compound has no adjuvant activity, does not cause the activation of antigen presenting cells, delivers mRNA encoding autoantigen, and can reconstruct the specific immune tolerance of an organism to the autoantigen, so that the purpose of fundamentally treating autoimmune diseases is achieved, and the compound has wide application prospects in the fields of autoimmune disease vaccine development, immunotherapy and the like.